Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Host: Jason J. Luke, MD, FACP
Guest: Tara C. Mitchell, MD
Guest: Tara C. Mitchell, MD
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.